dealingfloor.com

** MORNING WRAP **

** US MARKETS **
Dow -1,29%; Nasdaq -2,21%; S&P -1,36%; Soxx -2,35%; Russel2k -2,55%; DJAIG
2,12%; 10yr Bond 0,04%; 10yr Yield 4,53%; Crude future 60,21; Gold 638,7

| Energy -0,31%| Healthcare -0,64%| Telecom -0,76%| Utilities -0,89%|
ConsStaples -1,18%| Industrials -1,3%| ConsDisc -1,42%| Materials -1,51%|
Financials -1,62%| Technology -2,46%

- Palm Inc. dropped 62 cents, or 4 percent, to $14.75. The maker of the Treo
e-mail phone reduced its fiscal second-quarter profit forecast because of a
delay in getting approval for a new Treo device it had expected to ship during
the period. Second-quarter profit, excluding some items, may be as
much as 16 cents a share, the company said in a statement. That’s less than an
earlier prediction of as much as 23 cents. Palm said it expects to ship its Treo
750 phone in the U.S. in its fiscal third-quarter.

- On the economic front, Oct. Durable Orders will be released at 14:30 CET,
offering investors an update on the health of business investment, while
Consumer Confidence and Existing Home Sales will be out at 16:00 CET.

- Gold Falls as Investors Sell Ahead of U.S. Data, Speech by Fed Chairman (18:30
CET)

** ASIAN MARKETS **
Nikkei -0,19%; Kospi -0,96%; HSI -1,88%; Taiwan -0,71%; China -1,22%; India
-0,82%; Thailand -0,49%; Australia -1,19%

- Asian Stocks Drop, Led by Honda, Samsung on Slowing Sales in Japan, U.S.
- Japan’s Retail Sales Unexpectedly Drop as Consumers Spend Less on Clothes
- Volkswagen Plans to Spend $530 Million to Build Automobile Plant in India
- Hu Calls Bush, Pledging to Work for `Balance’ in U.S.-China Trade Links
- Xstrata May Seek More Copper Takeovers, Expand Production as Prices Soar
- Philippine Economic Growth Likely Slowed Amid Curbed Spending, Exports
- Copper in Shanghai Falls on Concern About China Imports, Slumping Demand

** EUROPE: IN PLAY TODAY **

- Multiplex Group, the Australian builder of London’s Wembley Stadium, will
start a real estate fund that invests in European property to increase earnings
from funds management. The Multiplex European Property Fund will initially own
67 German assets valued at 356 million euros ($468 million), the Sydney-based
company said in a statement today.

- Air Berlin Plc: Europe’s third-largest discount carrier plans to release
third-quarter results. The company will probably report a quarterly profit of 39
million euros, according to four analysts surveyed by Bloomberg News.

- ASM International NV: Shareholders of Europe’s second-largest
semiconductor-equipment maker rejected a minority investor’s proposal to break
up the company. The management said ASMI should continue as a combined company
and aims to achieve positive net earnings for its unprofitable front-end unit
next year. Mellon HBV Alternative Strategies LLC, owner of 8 percent
of ASMI, wants to split the company because it says such a move would increase
shareholder value.

- Banco Bilbao Vizcaya Argentaria SA: Spain’s second-biggest bank may be active
after the lender said it plans to raise 3 billion euros selling new shares to
boost core capital. The bank said it would offer the new shares to investors
over two days.

- BAE Ssystems: Saudi Arabia has suspended talks with the U.K. on a £10bn
Eurofighter Typhoon jet order, the Financial Times said, citing BAE Systems Plc
Chief Executive Officer Mike Turner. The talks on the contract are “not
currently moving forward” on completing the contract, Turner told the FT. A
deal may eventually be worth as much as £40bn to BAE, the newspaper said.

- EMI Chairman Eric Nicoli is talking to private equity groups that may include
KKR and Goldman Sachs Group Inc. over a potential £2.5bn bid for the U.K. music
co, the Financial Times said today, citing people familiar with the
negotiations. The talks for the London-based music company are early, and may
not come to fruition, or other parties may become involved, the newspaper said

- Novartis AG: Switzerland’s biggest drugmaker is scheduled to provide
information on its drugs under development. The Galvus diabetes pill is the
first of four new drugs Novartis plans to bring to market to counter patent
losses on older products.